Form 4: Coya Therapeutics Director Weinand Dieter Acquires 5,000 Stock Options
SEC Form 4 Filing
Director Weinand Dieter reports acquisition of 5,000 Coya Therapeutics stock options.
Summary
- On February 25, 2025, Dieter Weinand, a director of Coya Therapeutics, Inc., acquired 5,000 stock options.
- The options have an exercise price of $5.97.
- The options vest 100% on the first anniversary of the grant date, subject to continuous service.
- The options expire on February 25, 2035.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of transaction: Weinand Dieter acquired 5,000 stock options. |
| 02/25/2025 | Date of signature. |
| 02/25/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.